Therapy and Guidelines sub-committee
British Association of Dermatologists

Comments on the appraisal consultation for:
Single Technology Appraisal (STA)
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID567]

In response to the listed queries:

- Has all of the relevant evidence been taken into account? **This is not an area of practice for most dermatologists, who manage these patients in combination with rheumatologists. We are not aware of any missing evidence.**
- Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence? **The summaries appear to be a reasonable interpretation of the evidence given.**
- Are the provisional recommendations sound and a suitable basis for guidance to the NHS? **This is not an area of practice for most dermatologists, who manage these patients in combination with rheumatologists. The guidelines appear to request further information reflecting incomplete information, rather than providing at present a basis for guidance.**

Please tell us whether the preliminary recommendations:

- could have a different impact on people protected by the equality legislation than on the wider population, for example by making it more difficult in practice for a specific group to access the technology; **Not that we could determine.**
- could have any adverse impact on people with a particular disability or disabilities. **Not that we could determine.**

[redacted]